[1]
Reuben A, Tillman H, Fontana RJ, et al. Outcomes in adults with acute liver failure between 1998 and 2013. Ann Intern Med 2016; 164(11): 724-32.
[2]
Björnsson ES, Bergmann OM, Björnsson HK, Kvaran RB, Olafsson S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 2013; 144(7): 1419-25.
[3]
Aithal GP, Watkins PB, Andrade RJ, et al. Case definition and phenotype standardization in drug‐induced liver injury. Clin Pharmacol Ther 2011; 89(6): 806-15.
[4]
Fontana RJ. Acute liver failure due to drugs. Semin Liver Dis 2008; 28(2): 175-87.
[5]
Mendizabal M, Marciano S, Videla MG, et al. Changing etiologies and outcomes of acute liver failure: Perspectives from 6 transplant centers in Argentina. Liver Transpl 2014; 20(4): 483-9.
[6]
Goldberg DS, Forde KA, Carbonari DM, et al. Population-representative incidence of drug-induced acute liver failure based on an analysis of an integrated health care system. Gastroenterology 2015; 148(7): 1353-61.
[7]
Bessone F, Nelia H, Sanchez-Ciceron A, et al. A comparative analysis of the Spanish and Latin-American prospective druginduced liver injury (DILI) networks. Hepatology 2015; 62: 504.
[8]
Hernández N, Bessone F, Sánchez A, et al. Profile of idiosyncratic drug induced liver injury in Latin America: An analysis of published reports. Ann Hepatol 2014; 13(2): 231-9.
[9]
Bessone F, Colombato L, Fassio E, Reggiardo MV, Vorobioff J, Tanno H. The spectrum of nimesulide-induced-hepatotoxicity: An overview. Antiinflamm Antiallergy Agents Med Chem 2010; 9(4): 355-65.
[10]
Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: The diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol 2014; 109(7): 950-66.
[11]
Chalasani N, Bonkovsky HL, Fontana R, et al. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN prospective study. Gastroenterology 2015; 148(7): 1340-52.
[12]
Bessone F, Hernandez N, Mendizabal M, et al. When the creation of a consortium provides useful answers: Experience from the Latin-American DILI registry. Clin Liver Dis 2019; 13: 51-7.
[13]
Bessone F, Lucena MI, Roma MG, et al. Cyproterone acetate induces a wide spectrum of acute liver damage including corticosteroid‐responsive hepatitis: Report of 22 cases. Liver Int 2016; 36(2): 302-10.
[14]
Senior JR. Alanine aminotransferase: A clinical and regulatory tool for detecting liver injury-past, present, and future. Clin Pharmacol Ther 2012; 92(3): 332-9.
[15]
Danan G, Teschke R. RUCAM in drug and herb induced liver injury: The update. Int J Mol Sci 2015; 17(1): pii E14.
[16]
Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs. An original model for validation of drug causality assessment methods: Case reports with positive rechallenge. J Clin Epidemiol 1993; 46(11): 1331-6.
[17]
Reuben A, Koch DG, Lee WM. Drug‐induced acute liver failure: Results of a US multicenter, prospective study. Hepatology 2010; 52(6): 2065-76.
[18]
Davern TJ, Chalasani N, Fontana RJ, et al. Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology 2011; 141(5): 1665-72.
[19]
European Association for the Study of the Liver. EASL Clinical Practice Guidelines on hepatitis E virus infection. J Hepatol 2018; 68(6): 1256-71.
[20]
Björnsson E, Talwalkar J, Treeprasertsuk S, et al. Drug‐induced autoimmune hepatitis: Clinical characteristics and prognosis. Hepatology 2010; 51(6): 2040-8.
[21]
Roberts EA, Schilsky ML. American Association for the study of the Liver Disease. Diagnosis and treatment of Wilson disease: An update. Hepatology 2008; 47(6): 2089-111.
[22]
Korman JD, Volenberg I, Balko J, et al. Screening for Wilson disease in acute liver failure: A comparison of currently available diagnostic tests. Hepatology 2008; 48(4): 1167-74.
[23]
Lee WM, Stravitz RT, Larson AM. Introduction to the revised American Association for the study of liver diseases position paper on acute liver failure 2011. Hepatology 2012; 55(3): 965-7.
[24]
Stravitz RT, Lefkowitch JH, Fontana RJ, et al. Autoimmune acute liver failure: Proposed clinical and histological criteria. Hepatology 2011; 53(2): 517-26.
[25]
Mendizabal M, Marciano S, Videla MG, et al. Fulminant presentation of autoimmune hepatitis: Clinical features and early predictors of corticosteroid treatment failure. Eur J Gastroenterol Hepatol 2015; 27(6): 644-8.
[26]
Flamm SL, Yang YX, Singh S, Falck-Ytter YT. AGA American Gastroenterological Association Institute guidelines for the diagnosis and management of acute liver failure. Gastroenterology 2017; 152(3): 644-7.
[27]
Herrine SK, Moayyedi P, Brown RS, Falck-Ytter YT. American Gastroenterological Association Institute technical review on initial testing and management of acute liver disease. Gastroenterology 2017; 125(3): 648-64.
[28]
Kleiner DE, Chalasani NO, Lee WM, et al. The use of liver biopsy evaluation in discrimination of idiopathic autoinmune hepatitis versus drug induced liver injury. Hepatology (Baltimore, Md) 2013; 54(3): 931-9.
[29]
Robles–Diaz M, Lucena MI, Kaplowitz N, et al. Use of Hy’s law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury. Gastroenterology 2014; 147(1): 109-18.
[30]
Hayashi PH, Rockey DC, Fontana RJ, et al. Death and liver transplantation within 2 years of onset of drug‐induced liver injury. Hepatology 2017; 66(4): 1275-85.
[31]
Tujios SR, Lee WM. Acute liver failure induced by idiosyncratic reaction to drugs: Challenges in diagnosis and therapy. Liver Int 2018; 38(1): 6-14.
[32]
Lee WM, Hynan LS, Rossaro L, et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology 2009; 137(3): 856-64.
[33]
European Association for the Study of the Liver, Clinical practice guidelines panel, Wendon J, et al.. EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure. J Hepatol 2017; 66(5): 1047-81.
[34]
Larsen FS, Schmidt LE, Bernsmeier C, Rasmussen A, Isoniemi H, Patel VC. High-volume plasma exchange in patients with acute liver failure: An open randomised controlled trial. J Hepatol 2016; 64: 69-78.
[35]
Reddy KR, Ellerbe C, Schilsky M, et al. Determinants of outcome among patients with acute liver failure listed for liver transplantation in the United States. Liver Transpl 2016; 22(4): 505-15.
[36]
Habib S, Shaikh OS. Drug- induced acute liver failure. Clin Liver Dis 2017; 21(1): 151-62.
[37]
Robles-Díaz M, Medina-Caliz I, Stephens C, et al. Biomarkers in DILI: One more step forward. Front Pharmacol 2016; 7: 267.
[38]
Bessone F. Predicting fatalities in serious idiosyncratic drug-induced liver injury- a matter of choosing the best Hy’s law. Transl Gastroenterol Hepatol 2017; 2: 112.
[39]
Church RJ, Kullak‐Ublick GA, Aubrecht J, et al. Candidate biomarkers for the diagnosis and prognosis of drug‐induced liver injury: An international collaborative effort. Hepatology 2019; 69(2): 760-73.
106
4